Saturday 17 October 2026
Export VCYT’s income statement to Excel — free account
Veracyte, Inc.
VCYT Healthcare Diagnostics & Research
Veracyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $517.1 million, up 16.0% from fiscal 2024. In the quarter to June 2026, revenue grew 15.5%, EPS grew 3,300.0% and free cash flow grew 33.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
43.12
1.27
−2.86%
Follow VCYT
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
5 | 4 | 6 | 5 | 3 | 4 | 5 | 6 | 8 | 8 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 123.75 | 50.12 |
Altman Z-Score |
1.18 | (0.11) | 5.11 | 21.36 | 43.59 | 18.10 | 12.40 | 16.66 | 14.82 | 21.08 |
P/S ratio |
3.48 | 3.17 | 5.06 | 10.70 | 22.18 | 12.74 | 5.47 | 5.51 | 6.79 | 6.40 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 58.10 | 47.47 | 26.13 |
Altman Z″-Score (non-manufacturers) |
(2.19) | (6.58) | (0.95) | 7.80 | 14.93 | 12.15 | 13.61 | 14.92 | 10.40 | 15.66 |
P/Operating CF |
(53.48) | (39.20) | (379.86) | 719.65 | 1,152.37 | 331.17 | 166.32 | 127.99 | 123.50 | 62.92 |
Beneish M-Score |
(1.88) | (2.56) | (2.82) | (1.50) | (2.84) | (0.28) | (2.44) | (3.05) | (2.56) | (2.66) |
P/B ratio |
3.80 | 6.12 | 5.84 | 5.38 | 6.19 | 2.55 | 1.51 | 1.91 | 2.58 | 2.53 |
Price to Tangible BV |
5.10 | 9.87 | 6.98 | 7.50 | 7.27 | 15.05 | 7.93 | 7.88 | 9.24 | 7.30 |
EV/Sales |
2.98 | 3.07 | 4.49 | 9.40 | 19.23 | 11.95 | 4.87 | 4.92 | 6.15 | 5.60 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 69.86 | 38.17 |
EV/Operating CF |
(6.93) | (9.23) | (30.54) | (349.92) | (232.62) | (82.92) | 191.64 | 40.17 | 36.51 | 21.26 |
EV/FCF |
(6.02) | (8.75) | (26.83) | (189.60) | (180.03) | (70.87) | (1,424.06) | 51.84 | 42.97 | 22.88 |
Quick Ratio |
5.90 | 3.87 | 6.98 | 10.23 | 21.92 | 3.41 | 3.56 | 4.19 | 4.27 | 7.63 |
Current Ratio |
6.38 | 4.48 | 7.42 | 10.74 | 22.39 | 3.79 | 3.97 | 4.66 | 4.73 | 8.15 |
Net Debt/EBITDA |
1.30 | 0.39 | 2.88 | 14.43 | 12.63 | 2.83 | 11.80 | 3.66 | (7.37) | (5.44) |
Debt/Assets |
25.26% | 32.09% | 20.96% | 0.62% | 0.61% | 0.09% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.43 | 0.68 | 0.32 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.74 | 0.80 | 0.92 | 0.61 | 0.32 | 0.27 | 0.25 | 0.32 | 0.37 | 0.38 |
Operating CF/Net income |
0.89 | 0.77 | 0.59 | 0.26 | 0.28 | 0.42 | (0.21) | (0.59) | 3.11 | 2.05 |
Capex/Depreciation |
(1.54) | (0.30) | (0.47) | (0.65) | (0.36) | (0.27) | (0.33) | (0.37) | (0.49) | (0.53) |
Interest Coverage |
(10.45) | (5.37) | (11.33) | (22.34) | (154.54) | (606.69) | (20.83) | — | — | — |
| (56.59%) | (64.05%) | (39.32%) | (7.89%) | (10.57%) | (9.96%) | (3.37%) | (7.02%) | 2.17% | 5.34% | |
| (35.58%) | (34.50%) | (23.08%) | (6.37%) | (9.53%) | (9.19%) | (3.12%) | (6.55%) | 2.00% | 4.90% | |
ROIC |
(69.89%) | (58.03%) | (51.39%) | (11.55%) | (29.62%) | (5.56%) | (2.86%) | (6.48%) | 1.14% | 4.03% |
Return on Tangible Assets |
(42.62%) | (60.10%) | (24.77%) | (7.03%) | (9.49%) | (38.94%) | (17.95%) | (30.37%) | 7.62% | 14.72% |
Average Days of Receivables |
49.10 | 64.51 | 52.24 | 58.61 | 57.36 | 68.94 | 54.18 | 40.82 | 38.10 | 31.52 |
Research and Development Expense of Revenue |
23.54% | 19.29% | 16.11% | 12.34% | 14.64% | 13.60% | 13.69% | 15.87% | 15.54% | 13.69% |
Selling, General and Administrative Expense of Revenue |
79.95% | 76.92% | 70.95% | 68.72% | 75.86% | 82.54% | 57.58% | 51.99% | 46.22% | 40.79% |
Intangible Assets out of Total Assets |
0.15 | 0.18 | 0.11 | 0.25 | 0.14 | 0.77 | 0.75 | 0.71 | 0.65 | 0.61 |
Share Based Compensation of Revenue |
9.80% | 9.20% | 6.48% | 8.15% | 11.06% | 10.26% | 9.02% | 9.18% | 8.13% | 8.43% |
Graham Net Nets |
0.14 | 0.05 | 0.12 | 0.12 | 0.13 | 0.05 | 0.10 | 0.11 | 0.08 | 0.12 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.52 | 17.75 |
Earnings Yield |
(14.01%) | (13.54%) | (5.17%) | (0.95%) | (1.39%) | (2.77%) | (2.21%) | (3.76%) | 0.81% | 2.00% |
Free Cash Flow Yield |
(14.22%) | (11.07%) | (3.31%) | (0.46%) | (0.48%) | (1.32%) | (0.06%) | 1.72% | 2.11% | 3.83% |
Revenue per Share |
2.26 | 2.12 | 2.49 | 2.61 | 2.21 | 3.23 | 4.14 | 4.97 | 5.83 | 6.58 |
Operating CF per Share |
(0.97) | (0.70) | (0.37) | (0.07) | (0.18) | (0.47) | 0.11 | 0.61 | 0.98 | 1.73 |
Capex per Share |
(0.15) | (0.04) | (0.05) | (0.06) | (0.05) | (0.08) | (0.12) | (0.14) | (0.15) | (0.12) |
Free Cash Flow per Share |
(1.12) | (0.74) | (0.42) | (0.13) | (0.24) | (0.54) | (0.01) | 0.47 | 0.83 | 1.61 |
Cash per Share |
2.06 | 1.00 | 2.11 | 3.45 | 6.56 | 2.61 | 2.50 | 2.98 | 3.78 | 5.25 |
Shareholders Equity per Share |
2.07 | 1.10 | 2.15 | 5.19 | 7.91 | 16.15 | 15.03 | 14.37 | 15.38 | 16.66 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2.07 | 1.10 | 2.15 | 5.19 | 7.91 | 16.15 | 15.03 | 14.37 | 15.38 | 16.66 |
Free Cash Flow |
(32.19) | (25.23) | (15.39) | (5.96) | (12.55) | (37.00) | (1.01) | 34.26 | 63.81 | 126.63 |
Working Capital |
62.09 | 41.90 | 83.89 | 170.22 | 358.90 | 178.95 | 186.02 | 224.38 | 293.63 | 428.44 |
Capital Expenditures |
(4.21) | (1.31) | (1.87) | (2.73) | (2.84) | (5.38) | (8.55) | (9.96) | (11.29) | (9.68) |
Net Current Asset Value |
32.17 | 12.48 | 56.07 | 151.93 | 339.75 | 151.79 | 167.41 | 214.82 | 248.20 | 391.93 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 169.84 | 50.15 |
Capex to Sales |
0.06 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.02 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 187.64 | 57.26 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.24 | 0.45 | 0.44 | 0.47 | 0.88 | 1.30 | 1.46 | 1.30 | 1.01 | 0.82 |
Cash ROIC |
(22.29%) | (26.18%) | (8.41%) | (1.49%) | (1.62%) | (2.90%) | (0.08%) | 2.72% | 4.35% | 7.35% |
Accounts Receivable Turnover |
10.62 | 6.70 | 7.11 | 7.41 | 6.22 | 7.33 | 6.94 | 8.56 | 10.26 | 11.34 |
Accounts Payable Turnover |
6.78 | 8.98 | 10.39 | 15.08 | 15.23 | 9.61 | 9.96 | 10.57 | 13.68 | 23.38 |
Inventory Turnover |
7.03 | 6.41 | 7.58 | 7.16 | 7.23 | 9.37 | 9.47 | 8.64 | 7.79 | 7.31 |
Average Days of Payables |
34.75 | 49.88 | 27.76 | 23.27 | 27.44 | 60.64 | 35.97 | 35.96 | 21.35 | 10.84 |
Days of Inventory on Hand |
49.81 | 68.92 | 37.54 | 68.02 | 41.00 | 55.07 | 43.17 | 44.81 | 53.78 | 48.50 |
Average Receivables |
6.13 | 10.74 | 12.94 | 16.25 | 18.90 | 29.96 | 42.74 | 42.20 | 43.45 | 45.59 |
Average Payables |
3.75 | 3.14 | 3.18 | 2.42 | 2.72 | 7.74 | 12.14 | 12.43 | 10.79 | 6.61 |
Average Inventory |
3.62 | 4.40 | 4.36 | 5.10 | 5.73 | 7.94 | 12.76 | 15.21 | 18.94 | 21.15 |
Average Assets |
88.14 | 89.85 | 99.65 | 197.93 | 366.19 | 822.49 | 1,172.12 | 1,135.66 | 1,207.47 | 1,353.03 |
Average Common Equity |
55.42 | 48.40 | 58.49 | 159.61 | 330.34 | 758.87 | 1,085.86 | 1,059.65 | 1,110.03 | 1,242.77 |
Columns are period end dates